WHWK (Whitehawk Therapeutics) Marketable Securities: $88.25 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WHWK Whitehawk Therapeutics Inc WHWK
38 GF Score
Price $3.85
GF Value $0.27
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Whitehawk Therapeutics Marketable Securities?

Whitehawk Therapeutics WHWK +1.05% 38 Marketable Securities is $88.25 Mil as of Mar. 2026. GuruFocus rates WHWK with a GF Score™ of 38/100 and a GF Value™ of $0.27 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Whitehawk Therapeutics's Marketable Securities for the quarter that ended in Mar. 2026 was $88.25 Mil.

Whitehawk Therapeutics's annual Marketable Securities declined from Dec. 2023 ($45.96 Mil) to Dec. 2024 ($18.57 Mil) but then increased from Dec. 2024 ($18.57 Mil) to Dec. 2025 ($108.13 Mil).

Whitehawk Therapeutics  (NAS:WHWK) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Whitehawk Therapeutics Marketable Securities Related Terms

Whitehawk Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Whitehawk Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Whitehawk Therapeutics Marketable Securities Chart

Whitehawk Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 0.00 133.54 45.96 18.57 108.13

Whitehawk Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.49 32.26 124.67 108.13 88.25
WHWK
38GF Score
Whitehawk Therapeutics Inc WHWK
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Whitehawk Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $88.25 Mil mean?
Whitehawk Therapeutics (WHWK) has a Marketable Securities of $88.25 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Whitehawk Therapeutics and its competitors.
Is Whitehawk Therapeutics' Marketable Securities too high?
Whitehawk Therapeutics' current Marketable Securities is $88.25 Mil. Overall, Whitehawk Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Whitehawk Therapeutics' Marketable Securities compare to IMUX and TTRX?
Whitehawk Therapeutics' Marketable Securities of $88.25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Whitehawk Therapeutics and its competitors. Whitehawk Therapeutics's current Marketable Securities is $88.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Whitehawk Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Whitehawk Therapeutics (WHWK) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.27, compared to a current price of $3.85 — trading 1325.9% above its estimated fair value. The current Marketable Securities is $88.25 Mil. Whitehawk Therapeutics' overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Whitehawk Therapeutics (WHWK), the current Marketable Securities is $88.25 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Whitehawk Therapeutics (WHWK) Overvalued in 2026?

Based on GuruFocus' analysis, Whitehawk Therapeutics stock appears to be overvalued. The current stock price of $3.85 is trading 1325.9% above its estimated GF Value™ of $0.27. GuruFocus considers Whitehawk Therapeutics to be Significantly Overvalued.

Key valuation signals for WHWK:

  • Marketable Securities: $88.25 Mil
  • GF Value™: $0.27 vs. price of $3.85 (1325.9% above fair value)
  • GF Score™: 38/100 with 5 warning signs

No single metric tells the full story. See the WHWK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Whitehawk Therapeutics Business Description

Other Exchanges 3350:Germany
Address 2 Headquarters Plaza East Building, 11th Floor, Morristown, New Jersey, NJ, USA, 07960
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
38GF Score

Get the complete analysis for WHWK

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.85
Price
$0.27
GF Value